Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy ; volume:21 ; number:1 ; day:21 ; month:2 ; year:2023 ; pages:1 ; date:12.2023
World journal of surgical oncology ; 21, Heft 1 (21.2.2023), 1, 12.2023
- Urheber
-
Oner, Gizem
Önder, Semen
Karatay, Hüseyin
Ak, Naziye
Tükenmez, Mustafa
Müslümanoğlu, Mahmut
İğci, Abdullah
Dincçağ, Ahmet
Özmen, Vahit
Aydiner, Adnan
Yavuz, Ekrem
Cabioğlu, Neslihan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-023-02931-z
- URN
-
urn:nbn:de:101:1-2023042721134196872156
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Oner, Gizem
- Önder, Semen
- Karatay, Hüseyin
- Ak, Naziye
- Tükenmez, Mustafa
- Müslümanoğlu, Mahmut
- İğci, Abdullah
- Dincçağ, Ahmet
- Özmen, Vahit
- Aydiner, Adnan
- Yavuz, Ekrem
- Cabioğlu, Neslihan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Diagnostic biopsy does not accurately reflect the PD-L1 expression in triple-negative breast cancer
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
Expression von VISTA beim neoadjuvant behandelten Mammakarzinom : Korrelation mit PD-L1 und dem Therapieansprechen